Glioblastoma multiforme (GBM) is a malignant primary tumour. The presence of necrotic areas and atypical vascularisation as well as the presence of atypical cells with nuclear pleomorphism and high proliferative ratio constitute the most important features of this type of cancer. Despite many years of research, glioma is still the most deadly form of human cancer. It is, therefore, necessary to seek innovative experimental therapies to treat this type of tumour. Graphene and its derivates are a 2D carbon sheet with a honeycomb structure that exhibits extraordinary physical and electrical properties. One outstanding electrical feature of graphene is that its electron mobility derives from the presence of pi (π) electrons located above and below the graphene sheet. Graphene is characteristic of intensive biological activity that displays anticancer properties. In this research work 3 forms of graphene oxide plates (GO), 2 forms of graphene plates (GR), and 4 forms of reduced graphene oxide plates (rGO) were synthesised, described, and their influence on glioma IV cells was investigated, using U87, T98G and A172 cell lines as a model. Five concentrations of each of the plates: 5, 10, 25, 50, 100 µg/ml were tested. The morphology of cancer cells treated with GO, GR and rGO was assessed using the light microscopy. In order to determine the cytotoxic effect of plates on U87, T98G and A172 cell line, the Cell Proliferation Assay (MTT) and and Anexin V/PI Test were conducted. The viability of the cell lines was evaluated using the PrestoBlue® viability test. Each of the plates type had a differential effect on U87, T98G and A172 cell line. Six types of platelets reduced cell viability and proliferation with increasing doses but three of them increased the number of glioma cells and the mitochondrial metabolism. There wasn’t any interaction between the type of plates and cell effects. Graphene and its derivates have potential in glioma therapy but only after individual adjustment.
Journal: TechConnect Briefs
Volume: 3, Biotech, Biomaterials and Biomedical: TechConnect Briefs 2018
Published: May 13, 2018
Pages: 125 - 128
Industry sector: Medical & Biotech